At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,097 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration
In Brief
A Phase 3 clinical trial evaluating Ranibizumab for Age-related Macular Degeneration. Completed, enrolled 1,097 participants across 99 sites.
Detailed Summary
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJul 2009
Primary CompletionAug 2011
Study CompletionAug 2012
TodayJul 2026
First PostedMay 1, 2009
Enrollment StartJul 1, 2009
Primary CompletionAug 1, 2011
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.2 years ago
Interventions
Ranibizumabdrug
Sterile solution for intravitreal injection.